Description

Influenza virus inflicts a heavy death toll annually and resistance to existing antiviral drugs has generated interest in the development of agents with novel mechanisms of action. Favipiravir is an

Influenza virus inflicts a heavy death toll annually and resistance to existing antiviral drugs has generated interest in the development of agents with novel mechanisms of action. Favipiravir is an antiviral drug that acts by increasing the genome-wide mutation rate of influenza A virus (IAV). Potential synergistic benefits of combining oseltamivir and favipiravir have been demonstrated in animal models of influenza, but the population-level effects of combining the drugs are unknown.

Reuse Permissions
  • application/pdf

    Download count: 0

    Details

    Date Created
    • 2017-07-19
    Resource Type
  • Text
  • Collections this item is in
    Identifier
    • Digital object identifier: 10.1093/gbe/evx138
    • Identifier Type
      International standard serial number
      Identifier Value
      1759-6653
    Note

    Citation and reuse

    Cite this item

    This is a suggested citation. Consult the appropriate style guide for specific citation guidelines.

    Ormond, L., Liu, P., Matuszewski, S., Renzette, N., Bank, C., Zeldovich, K., . . . Wang, J. P. (2017). The Combined Effect of Oseltamivir and Favipiravir on Influenza A Virus Evolution. Genome Biology and Evolution, 9(7), 1913-1924. doi:10.1093/gbe/evx138

    Machine-readable links